The Group is fully aware that pharmaceutical companies are empowered by innovative research and development. It has determined the innovative research and development as its core strategic path and the combination of collaborative R&D and in-house R&D as the method to accelerate the pace of innovative research and development. So far the Group has participated in the equity investment of a number of R&D companies in the United Kingdom, France, the United States, Switzerland, etc. and has possessed innovative platform focused on neurological wellness, central nervous system, new approach to the treatment of infectious disease, nanomedicine therapy, acute thrombotic disease therapy, oral T-cell immunotherapy and the R&D of medicines for oncology and immunotherapy; at the same time, the Group has the assets and market rights of more than ten main innovative patented products under research in China and some Asia-Pacific countries. We will develop clinical trials and marketing plans in China based on the characteristics of each innovative patented products to bring more effective disease treatment drugs to Chinese doctors and patients.